92 Views | 132 Downloads
Dr. Jorge Cortes, Professor of Medicine and Internist, Deputy Chair and Chief, CML and AML Sections, Department of Leukemia, Division of Cancer Medicine, 1515 Holcombe Blvd, University of Texas MD Anderson Cancer Center, Houston, TX 77030. E‐mail: jcortes@mdanderson.org
We wish to thank all of the participating patients and their families, as well as the global network of investigators, research nurses, study coordinators, and operations staff.
J.E.C.: consultancy, research funding (Novartis, Bristol‐Myers Squibb, Pfizer, Ariad, Teva); H.J.K.: honoraria and membership on Board of Directors or advisory committees (Novartis, Bristol‐Myers Squibb, Pfizer, Ariad, and Teva); H.M.K.: research funding (Pfizer); J.H.L.: honoraria, membership on Board of Directors or advisory committees and speaker's bureaus, research funding (Pfizer, Bristol‐Myers Squibb, Novartis, Ariad); D.‐W.K.: consultancy, honoraria, research funding and membership on Board of Directors or advisory committees (Bristol‐Myers Squibb, Novartis, Pfizer, ILYANG); P.S.: consultancy, honoraria (Pfizer, Bristol‐Myers Squibb, Novartis, Ariad); T.H.B.: consultancy, honoraria (Bristol‐Myers Squibb, Pfizer, Novartis, Ariad), research funding (Novartis), as well as patents and royalties (use of imatinib and hypusination inhibitors); C.G.P.: consultancy (Pfizer, Bristol‐Myers Squibb) and research funding (Pfizer).
E.L. and K.N. are Pfizer employees.
E.M. was an employee of Pfizer when the manuscript was initiated.
This study was sponsored by Pfizer Inc. Editorial and medical writing support was provided by Johna Van Stelten, PhD, and Simon J. Slater, PhD, of Complete Healthcare Communications, LLC, and was funded by Pfizer Inc.
© 2016 Wiley Periodicals, Inc.